Raymond James analyst Steven Seedhouse reiterated a Buy rating on Chemocentryx Inc. on Monday, setting a price target of $120, which is approximately 75.44% above the present share price of $68.4.
Seedhouse expects Chemocentryx Inc. to post earnings per share (EPS) of -$0.35 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in ChemoCentryx (NASDAQ:CCXI), with an average price target of $98.5.
The analysts price targets range from a high of $120 to a low of $80.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $5.03 million and a net profit of -$23.86 million. The company's market cap is $4.73 billion.
According to TipRanks.com, Raymond James analyst Steven Seedhouse is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 15.4% and a 57.24% success rate.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.